Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

NCT05626101 is registered in ClinicalTrials.gov with Al-Azhar University as lead sponsor.

NCT NCT05626101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
Lead sponsor
Al-Azhar University
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2021
Completion date
October 11, 2024
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer